2025.12.25
On December 22, 2025, Simcere Zaiming announced that it has entered into an exclusive global licensing agreement, excluding Greater China, with French company Ipsen for an antibody-drug conjugate (ADC) SIM0613, which has the potential to be best-in-class.
SIM0613 targets the LRRC15 protein and can efficiently penetrate various solid tumors, offering potential treatment for certain solid tumors with urgent clinical needs.
Under the terms of the agreement, Simcere Zaiming could receive up to $1.06 billion in total transaction payments, including upfront payments, development, regulatory, and commercial milestone payments. Additionally, tiered royalties can be earned.
JunHe was entrusted by Simcere Zaiming to review, amend, and negotiate the agreement for this project. Throughout the project, JunHe earned the trust and recognition of its client through its consistently efficient, rigorous work style and meticulous, dedicated service attitude.
The lead partner for this project was lawyer ZHAO, Hao (Gerry).
